BMJ1d
Shared decision making in routine clinical care of patients with rheumatoid arthritis: an assessment of audio-recorded consultations
Objectives Although shared decision making (SDM) is advocated in rheumatoid arthritis (RA) treatment, it is largely unclear when, how and to what extent SDM is applied in routine clinical care of ...
BMJ2d
Low-ratio somatic NLRC4 mutation causes late-onset autoinflammatory disease
Objectives We aim to investigate the genetic basis of a case of late-onset autoinflammatory disease characterised by arthritis, recurrent fever and skin rashes. Methods We performed whole-exome/genome ...
BMJ3d
Defining refractory rheumatoid arthritis
While biologic disease-modifying antirheumatic drugs (bDMARDs) have transformed outcomes of people with rheumatoid arthritis (RA), a proportion of patients are refractory to multiple bDMARDs.
BMJ4d
Oral steroid in the treatment of carpal tunnel syndrome
Dr S M Wong, Department of Medicine, Prince of Wales Hospital, 30–32 Ngan Shing Street, Shatin, New Territories, Hong Kong, Special Administrative Region China If you wish to reuse any or all of this ...
BMJ6d
Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial
Objectives Oligoarticular psoriatic arthritis (PsA) is frequent but rarely studied. The objective was to assess the efficacy of apremilast in early oligoarticular PsA. Methods FOREMOST (NCT03747939) ...
BMJ7d
Ultrasensitive serum interferon-α quantification during SLE remission identifies patients at risk for relapse
1 Sorbonne Université, Assistance Publique–Hôpitaux de Paris, Groupement Hospitalier Pitié–Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody ...
BMJ12d
Development and validation of a methotrexate adherence assay
Correspondence to Dr James Bluett, Versus Arthritis Centre for Genetics and Genomics, Centre for Musculoskeletal Research, The University of Manchester, Manchester M13 9PT, UK; ...
BMJ12d
Instrument selection for the ASAS core outcome set for axial spondyloarthritis
23 National Institute for Health Research, University College London Hospitals Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK Objectives To define the ...
BMJ16d
Therapeutic interception in individuals at risk of rheumatoid arthritis to prevent clinically impactful disease
Multiple clinical trials for rheumatoid arthritis (RA) prevention have been completed. Here, we set out to report on the lessons learnt from these studies. Researchers who conducted RA prevention ...
BMJ17d
Protein kinase R is highly expressed in dermatomyositis and promotes interferon-beta-induced muscle damage
Objectives Dermatomyositis (DM) has been consistently linked to the type I interferon (IFN-I) pathway. However, the precise pathogenesis remains incompletely elucidated. We aimed to explore potential ...
BMJ17d
Correspondence on ‘EULAR recommendations for the management of systemic lupus erythematosus: 2023 update’ by Fanouriakis et al
We read with great interest the new EULAR guidelines1 for the management of systemic lupus erythematosus (SLE), and we appreciate the care taken in synthesising the newest research to advance best ...